Mirum Pharmaceuticals
MIRM
110 hedge funds and large institutions have $569M invested in Mirum Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 47 increasing their positions, 22 reducing their positions, and 11 closing their positions.
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
114% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 22
11% more funds holding
Funds holding: 99 → 110 (+11)
7.6% more ownership
Funds ownership: 84.5% → 92.11% (+7.6%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less capital invested
Capital invested by funds: $590M → $569M (-$21.1M)
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $603K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
+$15.1M |
| 2 |
BlackRock
New York
|
+$14.5M |
| 3 |
O
OrbiMed
New York
|
+$5.96M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$5.63M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.07M |
| 2 |
SCM
Sio Capital Management
New York
|
-$3.55M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.48M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.38M |
| 5 |
Axa
Paris,
France
|
-$2.3M |
MIRM Hedge Fund Activity: Q2 2022 in Review
110 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q2 2022, worth a combined $569M — down 3.6% from $590M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MIRM positions and 11 closed out — a net gain of 13 holders — while 47 added to existing stakes and 22 trimmed.
The largest buyer was Cadian Capital Management, adding an estimated $15.1M. The largest seller was Novo Holdings A/S, cutting an estimated $4.07M.
- 110 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q2 2022, up from 99 in Q1 2022.
- Funds reported $569M of Mirum Pharmaceuticals stock for Q2 2022, down 3.6% quarter-over-quarter.
- 24 funds opened new Mirum Pharmaceuticals positions in Q2 2022 and 11 closed out, a net change of +13 holders.
- The largest Mirum Pharmaceuticals buyer in Q2 2022 was Cadian Capital Management, an estimated $15.1M added.
- The largest Mirum Pharmaceuticals seller in Q2 2022 was Novo Holdings A/S, an estimated $4.07M sold.
Based on aggregated 13F filings for Q2 2022.